Development and characterization of a novel Cremophor? EL free liposome-based paclitaxel (LEP-ETU) formulation
Development and characterization of a novel Cremophor? EL free liposome-based paclitaxel (LEP-ETU) formulation
January 2005
Received 29 March 2004; accepted 7 June 2004. Available online 1 September 2004
J. Allen Zhang, Gopal Anyarambhatla1, Lan Ma1, Sydney Ugwu, Tong Xuan, Tommaso Sardone and Imran Ahmad
European Journal of Pharmaceutics and Biopharmaceutics
Volume 59, Issue 1 , January 2005, Pages 177-187
NeoPharm, Inc., Waukegan, IL, USA
Taxol? is a marketed product for the treatment of ovarian, breast, non-small cell lung cancer and AIDS-related Kaposi's Sarcoma. It is thus far one of the most effective anticancer drugs available on the market. However, paclitaxel is only sparingly soluble in water and therefore, intravenous administration depends on the use of the non-ionic surfactant Cremophor? EL (polyethoxylated castor oil) to achieve a clinically relevant concentrated solution. Unfortunately, Cremophor? EL increases toxicity and leads to hypersensitivity reactions in certain individuals. We have developed a well characterized novel lyophilized liposome-based paclitaxel (LEP-ETU) formulation that is sterile, stable and easy-to-use. The mean particle size of the liposomes is about 150 nm before and after lyophilization, and the drug entrapment efficiency is greater than 90%. Stability data indicated that the lyophilized LEP-ETU was physically and chemically stable for at least 12 months at 2?8 and 25 ?C. Moreover, the formulation can be diluted to about 0.25 mg/ml without drug precipitation or change in particle size. In vitro drug release study in phosphate-buffered saline (PBS, pH 7.4) showed that less than 6% of the entrapped paclitaxel was released after 120 h, indicating that the drug is highly stable in an entrapped form at physiologic temperature.
Keywords: Liposome-based formulation; Paclitaxel; Liposomes; Stability; Lyophilization; Taxol?; Entrapment
You can view the abstract online. A subscription is required to view the full text.
Comments: 0